Latest news with #PolyMedicure
&w=3840&q=100)
Business Standard
21 hours ago
- Business
- Business Standard
Poly Medicure to invest ₹500 cr in new plants for global market push
Poly Medicure to set up three plants in Faridabad, Haridwar, and Jaipur for dialysis, cardiology, and oncology devices, targeting US, Europe, and Brazil markets by FY28 Sanket Koul New Delhi Listen to This Article Delhi-based medical consumables and devices maker Poly Medicure is looking to significantly expand its global footprint, driven by new manufacturing facilities and an aggressive push into key export markets such as the United States (US), Brazil, and Europe. However, this foreign push comes at a time when the device maker faces short-term demand uncertainties due to ongoing geopolitical tensions and tariff issues. 'We are monitoring the evolving situation closely. For now, our plans for the US market remain unchanged,' Himanshu Baid, managing director, Poly Medicure, told Business Standard. 'We are working toward securing global regulatory approvals, including US Food and
Yahoo
a day ago
- Business
- Yahoo
Poly Medicure Ltd (BOM:531768) Q1 2026 Earnings Call Highlights: Strategic Expansion and ...
Release Date: August 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Poly Medicure Ltd (BOM:531768) was awarded Medical Device Provider of the Year 2025, highlighting its strong reputation in the healthcare sector. The company has signed two new contract manufacturing agreements, expanding its presence in the US and Hong Kong markets. Poly Medicure Ltd has established a wholly-owned subsidiary in Brazil, indicating a strategic move to expand its market presence in South America. The company's domestic revenue grew by 20% in Q1, with a significant increase in the private sector, reflecting a strong focus on sustainable domestic business. The company is investing in R&D, with a 20% increase in spending, to develop high-end technology segments such as cardiology and critical care. Negative Points International revenue saw a slight dip of 1% due to growth challenges in the European market and geopolitical uncertainties. The company faces challenges from tariffs imposed by the US, which could impact export markets. There is a slowdown in the infusion therapy business, primarily due to challenges in the European market. The company has lowered its international revenue growth guidance to 5-10% from the earlier 12-15%, reflecting current market uncertainties. The competitive intensity from Chinese companies in Europe has increased, affecting pricing and market dynamics. Q & A Highlights Warning! GuruFocus has detected 2 Warning Signs with BOM:531768. Q: Despite a lower international business, the gross margin was high during the quarter. What drove this margin, and what is sustainable for the full year? A: The gross margin historically tracks between 65% and 67%. As we delve deeper into critical cardiology areas, the product prices are higher, leading to higher gross margins. A run rate between 65% to 68% is sustainable. (Unidentified_3, Managing Director) Q: Can you explain the growth challenges in Europe and the expected easing in subsequent quarters? A: Europe faced financial restructuring and liquidity issues, leading to reduced inventory levels. However, demand is returning as inventory levels normalize, and we expect 5% to 10% growth in international business in the coming quarters. (Unidentified_3, Managing Director) Q: What are Poly Medicure's expansion plans for the HDF and CRRT portfolios in the renal segment? A: We plan to launch our first HDF machine in 2026, which is currently under development. CRRT is not a focus right now but may be considered for future development. (Unidentified_3, Managing Director) Q: Could you provide details on the contract manufacturing contracts in vascular and pain management? A: These are CDMO opportunities with innovative, patented devices. Revenue should start coming in from the next financial year, but it will take 2-3 years to scale up significantly. (Unidentified_3, Managing Director) Q: How is the company planning to address the competitive intensity from Chinese companies in Europe? A: The competitive intensity from Chinese companies has decreased, and we are seeing demand bounce back in Europe. We are confident that Europe will perform better in the current quarter. (Unidentified_3, Managing Director) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Business Standard
4 days ago
- Business
- Business Standard
Poly Medicure consolidated net profit rises 25.72% in the June 2025 quarter
Sales rise 4.79% to Rs 403.21 crore Net profit of Poly Medicure rose 25.72% to Rs 93.08 crore in the quarter ended June 2025 as against Rs 74.04 crore during the previous quarter ended June 2024. Sales rose 4.79% to Rs 403.21 crore in the quarter ended June 2025 as against Rs 384.78 crore during the previous quarter ended June 2024. Particulars Quarter Ended Jun. 2025 Jun. 2024 % Var. Sales 403.21384.78 5 OPM % 26.3227.01 - PBDT 146.20118.11 24 PBT 122.9598.46 25 NP 93.0874.04 26
&w=3840&q=100)
Business Standard
07-05-2025
- Business
- Business Standard
Poly Medicure Q4 results: Profit rises 34% on strong exports, new divisions
Delhi-based medical device manufacturer Poly Medicure on Wednesday announced a 34 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) for the March quarter of financial year 2024–25 (Q4FY25), driven by strong export revenue and the commercialisation of its new cardiology and critical care divisions. The company's PAT for the quarter was recorded at Rs 91.8 crore, up from Rs 68.4 crore in the same period last year. Its revenue from operations rose to Rs 440.8 crore in Q4FY25, a 16.6 per cent Y-o-Y rise from Rs 378.1 crore reported in Q4FY24. The company stated that its export revenue for the March quarter increased by 14 per cent year-on-year, driven by continued strong performance in key international markets. Exports formed around 67 per cent of the company's revenue mix—double that of the domestic market, which accounted for 32 per cent of overall revenue in Q4. Commenting on the performance, Himanshu Baid, managing director, Poly Medicure, said that while ongoing geopolitical conditions and uncertainty created by US-imposed tariffs may create short-term pressure on demand in certain export markets, India's Medtech sector is well positioned to benefit in the long term as global customers look to create alternate supply chains. At the operating level, Poly Medicure's earnings before interest, tax, depreciation, and amortisation (EBITDA) rose to Rs 119.5 crore, with an EBITDA margin of 27.1 per cent in the March quarter, compared to Rs 96.5 crore and 25.5 per cent, respectively, in the same period last financial year. Baid added that the company's margins have continued to expand at a higher scale of operations, giving it the confidence to continue investing capital in expanding manufacturing capacities. The company currently has 12 manufacturing facilities, with three more under construction in India. It has a portfolio of over 200 medical devices across 12 medical therapies, including infusion therapy, vascular access, dialysis and renal care, among others. On Wednesday, Poly Medicure's shares rose by 2.06 per cent, closing at Rs 2,835.65 apiece on the Bombay Stock Exchange (BSE).
&w=3840&q=100)
Business Standard
07-05-2025
- Business
- Business Standard
Medical device company share price zooms 47% in 1 month. Do you own?
Poly Medicure share price today: Shares of Poly Medicure, a leading medical device company with a dominant position in India's medical consumables market, rallied 5 per cent to ₹2,922 on the BSE in Wednesday's intra-day trade after it reported a healthy financial performance for the quarter ended March 2025 (Q4FY25). The stock price of the company is trading at its highest level in calendar year 2025. It had hit a 52-week high of ₹3,350 touched on November 1, 2024. In the past one month, the stock price of Poly Medicure has zoomed 47 per cent, as compared to 2.6 per cent rise in the BSE Sensex. At 10:31 am; Poly Medicure was trading 4 per cent higher at ₹2,884.90, as against 0.11 per cent decline in the benchmark index. Poly Medicure Q4 result Revenue from operations increased by 17 per cent to ₹440.80 crore in Q4FY25 over the previous year quarter. Export revenue growth was driven by continued strong performance in key international markets. Geopolitical tensions and tariff war has created short term demand uncertainty in certain export markets, the company said. Earnings before interest, taxes, depreciation, and amortisation (Ebitda) grew by 24 per cent to ₹119.5 crore in Q4FY25 on a YoY basis, reflecting strong earnings capability from core operations. Ebitda margin has improved by 160 bps to 27 per cent in Q4FY25. Profit after tax increased by 34 per cent in Q4FY25. Management commentary The current ongoing geopolitical condition as well as uncertainty created due to US imposed tariffs may create short term pressure on demand in certain export markets. The management believes that the India MedTech sector is well-positioned to benefit from this situation on a longer term basis as global customers look to create alternate supply chains. The company's investment in 3 new plants is going on strongly, which the management believes positions the company very strongly to achieve the significant growth opportunities. Crisil's view on Poly Medicure Continuous capacity addition and product innovation and development will support revenue growth over the medium term as well. Ebitda margin is expected to remain stable at 26-27 per cent over the medium term. The margin should be supported by better economies of scale, which in turn will be led by steady capacity utilisation, modernisation of facilities and cost-cutting initiatives. About Poly Medicure Poly Medicure is a leading medical device manufacturer and exporter from India, with its products sold in over 125 countries, making a significant global impact on healthcare. With a robust portfolio of over 200 medical devices and more than 300 patents, Polymed offers a comprehensive range of medical devices across 12 medical therapies, including infusion therapy, vascular access, dialysis and renal care, critical care, cardiology, oncology, transfusion, diagnostics, gastroenterology, anaesthesia and respiratory care, urology, and surgery and wound management.
